Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00002744
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
02/07/2017
Locations: Children's Hospital Medical Center - Cincinnati, Cincinnati, Ohio +2 locations
Conditions: Leukemia
Register for Updates
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemia
NCT00201721
Completed
This study aims to assess the rate of complete and overall response using rituximab and pentostatin with and without cyclophosphamide, to monitor and assess toxicity of this regimen, and to determine the overall and progression-free survival in CLL patients
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2017
Locations: Ohio State University, Columbus, Ohio
Conditions: B-Chronic Lymphocytic Leukemia
Register for Updates
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
NCT00323323
Completed
Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who have not had previous treatments. The biological response of lymphoma cells and the immune system to this drug combination will also be measured in patients before, during, and after therapy administration.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/19/2017
Locations: Ohio State University, Columbus, Ohio
Conditions: Non-Hodgkin's Lymphoma
Register for Updates
S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
NCT00005089
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage cancer cells. Combining chemotherapy with monoclonal antibody therapy and radiation therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effecti... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2017
Locations: Barrett Cancer Center, The University Hospital, Cincinnati, Ohio +6 locations
Conditions: Lymphoma
Register for Updates
Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT00873093
Completed
This pilot, phase II trial studies the side effects of giving bortezomib together with combination chemotherapy and to see how well it works in treating young patients with relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bor... Read More
Gender:
ALL
Ages:
Between 1 year and 31 years
Trial Updated:
11/30/2016
Locations: Children's Hospital Medical Center of Akron, Akron, Ohio +7 locations
Conditions: B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
Register for Updates
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00040937
Completed
RATIONALE: Thalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving thalidomide before and after peripheral stem cell transplant may be effective in treating newly diagnosed multiple myeloma. PURPO... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/26/2016
Locations: McDowell Cancer Center at Akron General Medical Center, Akron, Ohio +26 locations
Conditions: Multiple Myeloma
Register for Updates
Dose-Dense Docetaxel Before or After Doxorubicin/Cyclophosphamide in Axillary Node-Positive Breast Cancer
NCT00201708
Completed
This study will determine if docetaxel will be administered before or after doxorubicin/cyclophosphamides in an adjuvant chemotherapy regimen to be evaluated in a subsequent phase III trial.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/01/2016
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Breast Cancer
Register for Updates
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
NCT00020943
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and rituximab w... Read More
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
07/15/2016
Locations: Arthur G. James Cancer Hospital at Ohio State University, Columbus, Ohio
Conditions: Lymphoma
Register for Updates
Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00032019
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining rituximab with combination chemotherapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination chemotherapy in treating patients who have previous... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/15/2016
Locations: Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio
Conditions: Lymphoma
Register for Updates
Fludarabine and Cyclophosphamide Followed by Peripheral Stem Cell Transplant in Treating Patients With Leukemia or Lymphoma
NCT00006252
Completed
RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. PURPOSE: This phase II trial is studying how well fludarabine a... Read More
Gender:
ALL
Ages:
69 years and below
Trial Updated:
07/15/2016
Locations: Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus, Ohio
Conditions: Leukemia, Lymphoma
Register for Updates
Chemotherapy and Whole-Brain Radiation Therapy in Treating Patients With Primary Central Nervous System Non- Hodgkin's Lymphoma
NCT00002676
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells and may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and whole-brain radiation therapy in patients with primary central nervous system non-Hodgkin's lymph... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/12/2016
Locations: CCOP - Columbus, Columbus, Ohio +1 locations
Conditions: Lymphoma
Register for Updates
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Previously Untreated Aggressive Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
NCT00005964
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is most effective in treating aggressive non-Hodgkin's lymphoma. PURPOSE: Randomized phase II trial to compare the effectiveness of two combination chemotherapy regimens in treating patients who have previously untreated aggressive stage II, stage III... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/12/2016
Locations: Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio
Conditions: Lymphoma
Register for Updates